The ability of group B coxsackieviruses to produce pericarditis or myocarditis in man, particularly in infants, is well recognized, (1, 3, 8, 9, 17, 18, 28) . However, a clear-cut laboratory diagnosis of group B coxsackievirus infection, based upon virus isolation or demonstration of a significant rise in antibody titer during the course of illness, can be established only infrequently in sporadic cases of pericarditis or myocarditis (2, 10, 11, 27) . In cases of pleurodynia, recovery of coxsackievirus or significant rises in antibody titer, or both, are more frequently demonstrable, but there is still a fairly high proportion of sporadic cases in which there are no positive laboratory findings. For example, in 1970, the period covered by this report, specimens were submitted to this laboratory on more than 250 patients with a clinical diagnosis of pericarditis, myocarditis, or pleurodynia; a group B coxsackievirus was isolated from two patients with chest pain compatible with a clinical diagnosis of pleurodynia, and one patient with a clinical diagnosis of pericarditis showed fourfold or greater rises in neutralizing antibody titer to three types of group B coxsackievirus.
It has been speculated that pericarditis, myocarditis, or pleurodynia may occur relatively late in the course of coxsackievirus infections, at a time when antibody levels are already elevated and virus is no longer being shed or is combined with antibody.
Previous studies from this laboratory have shown that immunoglobulin (Ig) M antibody to group B coxsackievirus types 1, 3, 4, 5, and 6 and group A, type 9 can be demonstrated by immunodiffusion tests (24) (25) (26) . IgM antibody reacts type-specifically with the intact virion of coxsackieviruses and forms an immunoprecipitate distinct from that produced by IgG antibody and empty capsids. It has also been shown that the initial antibody response to group B coxsackievirus infections consists of the production of IgM antibody, which is gradually replaced in 4 to 6 weeks by IgG (26 the acute-phase specimen, and there was wide variation in the collection times of the convalescent-phase sera from these patients in which IgM antibody was no longer demonstrable. None of the three convalescent-phase sera collected later than 42 days after onset had demonstrable IgM antibody, and all of the single serum specimens which contained IgM antibody were collected less than 36 days after onset of illness.
Virus isolation attempts on pericarditis, myocarditis, or pleurodynia patients. Efforts to recover a coxsackievirus from patients in the study group are summarized in Table 6 . It is seen that virus isolation attempts were performed in 113 of the cases, none of which yielded a virus. Approximately equal numbers of patients without isolation attempts and with negative results had IgM antibody to group B coxsackieviruses. For the patients with negative results, most of the specimens tested were fecal specimens, and approximately one-half of the isolation attempts were made on specimens collected within the first week after onset of illness. Thus, negative virus isolation results were obtained despite the fact that appropriate specimens collected at suitable times were examined. This is in marked contrast to the experience in this laboratory with cases of aseptic meningitis due to coxsackieviruses in which the virus is readily recovered from stools and spinal fluid in a high proportion of cases. However, 30% of the pericarditis, myocarditis, or pleurodynia patients with negative isolation results possessed IgM antibody for group B coxsackieviruses.
Place of residence and months of onset for patients in study and control groups. Approximately 70% of the patients in both the study group and the control group were from eight counties in the San Francisco Bay area. The remainder of the patients in each group were distributed throughout 16 other counties in California. Of the patients who had IgM antibody to group B coxsackieviruses, 42 of 70 in the study group and 10 of 21 in the control group were from the San Francisco Bay area. Table 7 shows the month of onset of illness for patients in the study group and the control group and the occurrence of IgM antibody by month of onset. The number of pericarditis, myocarditis, or pleurodynia patients was high in January, decreased during the spring and summer months, and increased in the autumn and early winter months. For the most part, the occurrence of IgM in the study group followed this same pattern. The demonstration of IgM antibody in the control group was also more It is noteworthy that, although group B coxsackieviruses are the principal agents suspected in virtually all of the cases of pericarditis or myocarditis on whom clinical specimens are submitted to our laboratory for virological studies, nearly three-fourths of the cases in the present study failed to show evidence of a current or recent coxsackievirus infection. It should be emphasized, however, that clinical diagnoses in this study were taken from laboratory request forms and accompanying correspondence and were not further substantiated.
IgM antibody for coxsackievirus types Bi, B3, B4, B5, and B6 can be demonstrated relatively simply by micro-immunodiffusion techniques which lend themselves to large-scale studies. However, antigens used for detection of IgM antibody must be prepared from infected tissue culture fluids with high infectivity titers, since it is the intact virion with which the IgM antibody reacts (22, 26) . Demonstration of IgM antibody for coxsackievirus type B2 is more complex, since it is based upon dissociating the IgM antibody with a sulfhydryl reducing agent and then assaying for neutralizing antibodies. However, the use of a micro-colorimetric neutralization test (21) greatly facilitates this procedure.
The fact that IgM antibody to group B coxsackieviruses was found in a relatively high proportion of patients from whom it was impossible to recover virus would be in keeping with the view that pericarditis and myocarditis are likely to be late events in the course of coxsackievirus infections, at a time when virus excretion has ceased or virus is masked by antibody. The possibility also exists that coxsackievirus infections complicated by pericarditis, myocarditis, or pleurodynia may result in a prolonged production of IgM antibody. Prolonged rubella IgM antibody production has been noted in rubella infections complicated by thrombocytopenic purpura or carpal-tunnel compression (7), and prolonged persistence of IgM antibody to measles virus has been found in some patients with subacute sclerosing panencephalitis (5) and multiple sclerosis (14) .
Several other investigations have suggested the association of group B coxsackieviruses with a high proportion of sporadic pericarditis or myocarditis cases (2, 11, 20, 27) , but in each of these studies there were very few cases in which virus was isolated or significant increases in antibody titer could be demonstrated. Instead, the possible association of coxsackieviruses was based, in most cases, upon the presence of (4, 12, 23) that the demonstration of a declining titer may be coincidental, the antibody having been elicited by a long-past infection not associated with the patient's present illness. Thus the diagnostic significance of stationary or declining levels of neutralizing antibody to coxsackieviruses in patients with cardiac disease is highly equivocal, especially in the absence of comparative data on antibody levels in a control group. In the present study on IgM antibody to coxsackieviruses, the spectrum of patients available for study did not permit an exact matching with respect to age and dates of onset in the study and control groups; however, the two groups were not greatly disparate and the likelihood of finding coxsackievirus IgM antibody would appear to have been weighted in favor of the control group, since it contained a greater number of patients in childhood age (6, 16) . Also, overlapping symptoms such as cough and chest pain may occur in pleurodynia or pneumonia, and in the absence of more precise clinical records and X-ray findings allowance should be made in our findings for possible inaccuracies in the clinical diagnosis.
